劲方医药(02595.HK)直肠癌联合疗法拟纳入突破性疗法认定名单

阿斯达克财经
Sep 22

劲方医药-B(02595.HK) 表示,董事会注意到公司股份价格近日有所上升,并知会股东及潜在投资者有关集团最新业务动态,旗下临床项目GFH375联合西妥昔单抗联合疗法,于上周五(18日)获国家药督局药品审评中心拟纳入突破性疗法认定名单,治疗既往经奥沙利铂、氟尿嘧啶类和伊立替康为基础的化疗失败的KRAS G12D突变型转移性结直肠癌。该临床项目于今年8月13日申请,公示截止日期为今年9月24日。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10